回复：对ProfiLER-02研究设计和结果的关键评价

IF 50 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-09-10 DOI:10.1038/s41591-025-03960-9

Olivier Trédan, Marie-Sarah Cabrillac, Sylvie Chabaud, Gwenaelle Garin, David Pérol, Jean-Yves Blay

{"title":"回复：对ProfiLER-02研究设计和结果的关键评价","authors":"Olivier Trédan, Marie-Sarah Cabrillac, Sylvie Chabaud, Gwenaelle Garin, David Pérol, Jean-Yves Blay","doi":"10.1038/s41591-025-03960-9","DOIUrl":null,"url":null,"abstract":"replying to Subbiah & Kurzrock. Nature Medicine https://doi.org/10.1038/s41591-025-03959-2 (2025)We thank V. Subbiah and R. Kurzrock for their interest in the ProfiLER-02 study1,2 and for the opportunity to clarify several aspects of our work. Their comments highlight key challenges in the design and interpretation of precision oncology clinical trials.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"57 1","pages":""},"PeriodicalIF":50.0000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to: Critical evaluation of the ProfiLER-02 study design and outcomes\",\"authors\":\"Olivier Trédan, Marie-Sarah Cabrillac, Sylvie Chabaud, Gwenaelle Garin, David Pérol, Jean-Yves Blay\",\"doi\":\"10.1038/s41591-025-03960-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"replying to Subbiah & Kurzrock. Nature Medicine https://doi.org/10.1038/s41591-025-03959-2 (2025)We thank V. Subbiah and R. Kurzrock for their interest in the ProfiLER-02 study1,2 and for the opportunity to clarify several aspects of our work. Their comments highlight key challenges in the design and interpretation of precision oncology clinical trials.\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"57 1\",\"pages\":\"\"},\"PeriodicalIF\":50.0000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-025-03960-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03960-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

回复Subbiah &； Kurzrock。Nature Medicine https://doi.org/10.1038/s41591-025-03959-2（2025）我们感谢V. Subbiah和R. Kurzrock对ProfiLER-02研究的兴趣，并有机会澄清我们工作的几个方面。他们的评论强调了精确肿瘤学临床试验设计和解释中的关键挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Reply to: Critical evaluation of the ProfiLER-02 study design and outcomes

replying to Subbiah & Kurzrock. Nature Medicine https://doi.org/10.1038/s41591-025-03959-2 (2025)

We thank V. Subbiah and R. Kurzrock for their interest in the ProfiLER-02 study^1,2 and for the opportunity to clarify several aspects of our work. Their comments highlight key challenges in the design and interpretation of precision oncology clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.